ALXO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALX Oncology Holdings Inc (ALXO) is not a strong buy for a beginner, long-term investor at this time. While the company has promising clinical advancements and an extended cash runway, its financial performance remains weak, with ongoing losses and missed earnings expectations. The technical indicators and trading signals do not suggest a compelling entry point, and the stock's short-term trend indicates potential downside risks. It is advisable to monitor the stock for further developments or better entry points.
The MACD histogram is -0.0653, below 0, and negatively expanding, indicating bearish momentum. RSI is neutral at 40.282, and moving averages are converging, showing no clear trend. Key support levels are at 2.066 and 1.915, while resistance levels are at 2.555 and 2.706. The stock's short-term trend suggests a 70% chance of a 3.27% increase in the next day but a -8.83% decrease in the next week.
Significant clinical advancements with Evorpacept and ALX2004, with pivotal study readiness expected by the end of next year.
Completion of a $150 million financing round, extending cash runway through the first half of
Positive updates from ASPEN-06 gastric cancer and Phase 1b/2 breast cancer trials, validating efficacy and boosting confidence in ongoing trials.
Q4 2025 financial results showed a net loss of $22.8 million, down 21.65% YoY, and EPS of -$0.42, missing expectations by $0.
Stock trend analysis indicates potential short-term downside risks, with an 8.83% decline expected in the next week.
No significant hedge fund or insider trading activity to indicate strong confidence in the stock.
In Q4 2025, ALX Oncology reported a net income loss of $22.85 million, down 21.65% YoY, and an EPS of -0.42, down 22.22% YoY. Revenue and gross margin remained at 0, showing no growth. The company continues to face profitability challenges despite reduced spending.
Piper Sandler raised the price target from $3 to $4 and maintained an Overweight rating, reflecting optimism about recent updates and clinical progress. However, the stock's current price is significantly below the updated target, indicating a high-risk, high-reward scenario.
